Monte Rosa Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$1.80 | $0.02 | -$0.58 |
| Q2 2024 | 2 | -$1.61 | $0.02 | -$0.52 |
| Q3 2024 | 3 | -$1.46 | $0.02 | -$0.47 |
| Q4 2024 | 5 | $0.13 | $0.25 | $0.18 |
| Q1 2025 | 3 | -$0.44 | -$0.24 | -$0.37 |
| Q2 2025 | 2 | -$1.14 | $0.01 | -$0.37 |
| Q3 2025 | 2 | -$1.14 | $0.01 | -$0.37 |
| Q4 2025 | 2 | -$1.18 | $0.02 | -$0.38 |
Monte Rosa Therapeutics, Inc. Earnings Date And Information
Monte Rosa Therapeutics, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $-0.29 earnings per share for the quarter, topping analysts' consensus estimates of $-0.45 by $0.16. The company had revenue of 9.22 M for the quarter and had revenue of 0 for the year. Monte Rosa Therapeutics, Inc. has generated $-3 earnings per share over the last year ($-2.63 diluted earnings per share) and currently has a price-to-earnings ratio of -5.74. Monte Rosa Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based on prior year's report dates.
Monte Rosa Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | -$0.45 | -$0.29 | 0.16 | $2.64 M | $9.22 M |
| 08/08/2024 | Q2 2024 | -$0.50 | -$0.43 | 0.07 | $1.35 M | $4.70 M |
| 05/09/2024 | Q1 2024 | -$0.56 | -$0.53 | 0.03 | $1.06 M | |
| 03/14/2024 | Q4 2023 | -$0.57 | -$0.58 | -0.01 | $8.75 M | |
| 11/09/2023 | Q3 2023 | -$0.75 | -$0.70 | 0.05 | $0 | |
| 08/10/2023 | Q2 2023 | -$0.72 | -$0.71 | 0.01 | $0 | |
| 05/11/2023 | Q1 2023 | -$0.70 | -$0.60 | 0.1 | $0 | |
| 03/16/2023 | Q4 2022 | -$0.64 | -$0.59 | 0.05 | $0 | |
| 11/10/2022 | Q3 2022 | -$0.61 | -$0.56 | 0.05 | $0 | |
| 08/11/2022 | Q2 2022 | -$0.54 | -$0.55 | -0.01 | $0 | |
| 05/11/2022 | Q1 2022 | -$0.53 | -$0.51 | 0.02 | $0 | |
| 03/29/2022 | Q4 2021 | -$0.51 | $0 | |||
| 11/10/2021 | Q3 2021 | -$0.46 | -$0.43 | 0.03 | $0 | |
| 08/12/2021 | Q2 2021 | -$0.40 | -$3.63 | -3.23 | $0 | |
| 03/30/2021 | Q1 2021 | -$0.29 | $0 | |||
| 12/30/2020 | Q4 2020 | -$0.90 | $0 | |||
| 09/29/2020 | Q3 2020 | -$0.30 | $0 | |||
| 06/29/2020 | Q2 2020 | -$0.25 | $0 | |||
| 03/30/2020 | Q1 2020 | -$0.20 | $0 |
Monte Rosa Therapeutics, Inc. Earnings: Frequently Asked Questions
-
When is Monte Rosa Therapeutics, Inc.'s earnings date?
Monte Rosa Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 13th, 2025 based off last year's report dates.
-
Did Monte Rosa Therapeutics, Inc. beat their earnings estimates last quarter?
In the previous quarter, Monte Rosa Therapeutics, Inc. (:GLUE) reported $-0.29 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.45 by $0.16.
-
How can I listen to Monte Rosa Therapeutics, Inc.'s earnings conference call?
The conference call for Monte Rosa Therapeutics, Inc.'s latest earnings report can be listened to online.
-
How can I read Monte Rosa Therapeutics, Inc.'s conference call transcript?
The conference call transcript for Monte Rosa Therapeutics, Inc.'s latest earnings report can be read online.
-
How much profit does Monte Rosa Therapeutics, Inc. generate each year?
Monte Rosa Therapeutics, Inc. (:GLUE) has a recorded net income of $0. Monte Rosa Therapeutics, Inc. has generated $-2.63 earnings per share over the last four quarters.
-
What is Monte Rosa Therapeutics, Inc.'s price-to-earnings ratio?
Monte Rosa Therapeutics, Inc. (:GLUE) has a price-to-earnings ratio of -5.74 and price/earnings-to-growth ratio is -0.18.
